BidaskClub upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a hold rating to a buy rating in a research report released on Thursday.
Several other equities research analysts have also recently commented on ACHN. TheStreet cut Achillion Pharmaceuticals from a c- rating to a d rating in a research note on Wednesday, March 22nd. Robert W. Baird raised their target price on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the stock an outperform rating in a research note on Monday, April 24th. Maxim Group reduced their price objective on Achillion Pharmaceuticals from $8.00 to $5.00 and set a buy rating for the company in a research note on Tuesday, April 25th. Jefferies Group LLC reissued a hold rating on shares of Achillion Pharmaceuticals in a research note on Wednesday, April 26th. Finally, Zacks Investment Research cut Achillion Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $8.75.
Achillion Pharmaceuticals (NASDAQ ACHN) opened at 4.49 on Thursday. Achillion Pharmaceuticals has a 12 month low of $3.15 and a 12 month high of $9.49. The company has a 50 day moving average price of $4.29 and a 200 day moving average price of $4.09. The firm’s market capitalization is $613.89 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. During the same period last year, the firm posted ($0.13) EPS. Analysts anticipate that Achillion Pharmaceuticals will post ($0.64) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Achillion Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock valued at $40,357,000 after buying an additional 646,415 shares during the last quarter. State Street Corp boosted its position in shares of Achillion Pharmaceuticals by 40.1% in the fourth quarter. State Street Corp now owns 5,121,160 shares of the biopharmaceutical company’s stock valued at $21,153,000 after buying an additional 1,465,723 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Achillion Pharmaceuticals by 3.8% in the first quarter. Wellington Management Group LLP now owns 1,734,482 shares of the biopharmaceutical company’s stock valued at $7,303,000 after buying an additional 64,049 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Achillion Pharmaceuticals by 42.9% in the first quarter. Teachers Advisors LLC now owns 1,347,858 shares of the biopharmaceutical company’s stock valued at $5,674,000 after buying an additional 404,317 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $4,623,000. 71.26% of the stock is currently owned by institutional investors.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.